NewAmsterdam Pharma Co N.V.
NAMSW- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001936258
In the last 90 days, NewAmsterdam Pharma Co N.V. insiders filed 1 open-market purchase and 3 sales; 9 institutions reported holding it in 13F filings for Q2 2026, worth $28.1M in total; no superinvestor holds it.
Other share classesNAMS
13F holders, Q3 2023
Institutional positions in NewAmsterdam Pharma Co N.V. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 19
- 0 vs. Q2 2023
- Shares held
- 1.55M
- +62.6K (+4.2%) vs. Q2 2023
- Total value
- $3.49M
- −$1.24M (−26.1%) vs. Q2 2023
- New holders
- 1
- 1 more added
- Sold out
- 1
- 3 more reduced
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting NAMSW on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 9 | $28.1M |
| Q1 2026 | 9 | $26.0M |
| Q4 2025 | 9 | $29.9M |
| Q3 2025 | 9 | $22.2M |
| Q2 2025 | 10 | $10.4M |
| Q1 2025 | 10 | $12.3M |
| Q4 2024 | 11 | $18.8M |
| Q3 2024 | 11 | $9.32M |
| Q2 2024 | 10 | $11.5M |
| Q1 2024 | 11 | $15.9M |
| Q4 2023 | 18 | $5.65M |
| Q3 2023 | 19 | $3.49M |
| Q2 2023 | 19 | $4.73M |
| Q1 2023 | 19 | $5.00M |
| Q4 2022 | 22 | $4.53M |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 1 | $35.5K |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding NewAmsterdam Pharma Co N.V.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 500,333 | $950.6K | 0.06% | 00.0% | Unchanged |
| Ra Capital Management, L.P. | 333,333 | $633.3K | 0.01% | 00.0% | Unchanged |
| EcoR1 Capital, LLC | 66,665 | $616.7K | 0.02% | 00.0% | Unchanged |
| Affinity Asset Advisors, LLC | 137,000 | $260.3K | 0.09% | +100,000+270.3% | Added |
| Ensign Peak Advisors, Inc | 150,000 | $255.0K | 0.00% | 00.0% | Unchanged |
| Bain Capital Life Sciences Investors, LLC | 100,000 | $190.0K | 0.02% | 00.0% | Unchanged |
| Deerfield Management Company, L.P. (Series C) | 92,787 | $176.3K | 0.00% | 00.0% | Unchanged |
| Highbridge Capital Management LLC | – | $92.1K | 0.01% | – | – |
| HRT Financial LP | 30,321 | $57.0K | 0.00% | 00.0% | Unchanged |
| Westchester Capital Management, LLC | 31,189 | $54.6K | 0.00% | 00.0% | Unchanged |
| Walleye Capital LLC | 22,658 | $43.0K | 0.00% | −9,600−29.8% | Reduced |
| PEAK6 Investments LLC | 17,000 | $32.3K | 0.00% | 00.0% | Unchanged |
| Laurion Capital Management LP | 16,666 | $31.7K | 0.00% | 00.0% | Unchanged |
| Clear Street LLC | 13,463 | $25.6K | 0.00% | 00.0% | Unchanged |
| Walleye Trading LLC | 13,084 | $24.9K | 0.00% | −5,400−29.2% | Reduced |
| Exos TFP Holdings LLC | 12,273 | $23.3K | 0.01% | −10,000−44.9% | Reduced |
| Vestcor Inc | 9,632 | $18.0K | 0.00% | 00.0% | Unchanged |
| Cutler Group LP | 4,960 | $9.00K | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 38 | $72 | 0.00% | +38 | New |
| Wolverine Asset Management LLC | 0 | $0 | 0.00% | −12,448−100.0% | Sold out |